Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(6), 1880-1885 | ISSN:2251-6727

A Cross-Sectional Study of Renal Autoregulation in Hypertensive & Normotensive Individuals

Dr. Anand K S S[1], Dr. K. S. Priyadarshini[2]

[1]Professor and HOD, Adichunchanagiri Institute of Medical Science BG. Nagara, India.

[2]Professor, Department of Biochemistry, RRMCH, Bangalore, India.

Corresponding Author: Dr Anand K S S Professor and HOD, Adichunchanagiri Institute of Medical Science BG. Nagara, India.

(Received: 16 September 2024 Revised: 11 October 2024 Accepted: 11 December 2024)

KEYWORDS

Hypertension, Renal Autoregulation, Glomerular Filtration Rate.

ABSTRACT:

Background: Hypertension is a significant risk factor for renal dysfunction, influencing renal autoregulation and potentially leading to chronic kidney disease. Understanding the differences in renal autoregulation between hypertensive and normotensive individuals may provide insights into the mechanisms underlying hypertensive renal damage and inform therapeutic strategies

Methods: This cross-sectional study involved 700 participants, evenly split between hypertensive (n=353) and normotensive (n=347) individuals, recruited from a tertiary care center. We assessed renal autoregulation by measuring renal blood flow and glomerular filtration rate (GFR) using non-invasive imaging techniques. Statistical analysis included unpaired t-tests to compare means, chi-square tests for categorical variables, and calculation of 95% confidence intervals (CIs) and P values.

Results: The study found significant differences in renal blood flow and GFR between the groups. Hypertensive individuals demonstrated a lower renal blood flow (620.3 ± 90.2 mL/min) and GFR (88.4 ± 12.6 mL/min/1.73 m²) compared to normotensive controls (680.5 ± 75.4 mL/min and 94.7 ± 11.3 mL/min/1.73 m², respectively), with P values of 0.0003 and <0.001. Additionally, the pressure range for effective renal autoregulation was narrower in hypertensives (85-125 mmHg) than in normotensives (95-135 mmHg), indicating a significant shift ($P < 0.001$). Therapeutic interventions showed non-significant improvements in autoregulation among hypertensives.

Conclusion: The study underscores significant alterations in renal autoregulation associated with hypertension, characterized by reduced renal blood flow and GFR, along with a narrowed autoregulatory pressure range. These findings highlight the potential for targeted therapeutic strategies to mitigate hypertension-induced renal damage, although further research is necessary to evaluate the efficacy of such interventions.

INTRODUCTION

Renal autoregulation represents a critical physiological process by which the kidneys maintain a constant renal blood flow and glomerular filtration rate despite fluctuations in systemic blood pressure. This mechanism is vital for protecting the kidneys from the damaging effects of high blood pressure, which is particularly relevant in individuals with hypertension. The kidney's ability to autoregulate involves complex interactions between the myogenic response of renal blood vessels and the tubuloglomerular feedback from the juxtaglomerular apparatus. However, in hypertensive patients, these regulatory mechanisms may be impaired, leading to an increased risk of renal damage and chronic kidney disease.[1][2][3]

The study of renal autoregulation in hypertensive versus normotensive individuals can provide insights into the pathophysiological changes that hypertension may induce in renal blood flow dynamics. Research has shown that hypertensive patients often exhibit a shift in the pressure range over which autoregulation occurs, potentially exposing the kidneys to higher pressures and increasing the risk of hypertensive nephropathy. Such alterations can have significant clinical implications, influencing the management strategies for patients with hypertension to prevent renal complications.[4][5]

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(6), 1880-1885 | ISSN:2251-6727

Previous studies have utilized various methods to assess renal autoregulation, including measurements of renal blood flow using Doppler ultrasound and analysis of renal vascular resistance. These studies have helped establish the foundational understanding of how renal autoregulation differs between hypertensive and normotensive individuals. Nonetheless, there is a need for more comprehensive research with larger sample sizes to better delineate these differences and to explore potential therapeutic targets to protect renal function in hypertensive patients.[6][7][8]

Aim

To assess and compare renal autoregulation in hypertensive and normotensive individuals.

Objectives

1. To measure and analyze changes in renal blood flow and glomerular filtration rate in hypertensive versus normotensive individuals.
2. To evaluate the shift in the pressure range of renal autoregulation in hypertensive patients compared to normotensive controls.
3. To explore potential therapeutic interventions to enhance renal autoregulation in hypertensive patients.

MATERIAL AND METHODOLOGY

Source of Data: The study utilized patient data collected from hospital records and direct patient assessments at the medical center.

Study Design: A cross-sectional analytical study design was employed to assess renal autoregulation in hypertensive and normotensive individuals.

Study Location: The study was conducted at the renal unit of a large tertiary care hospital.

Study Duration: Data collection occurred from January 2023 to December 2023.

Sample Size: A total of 700 participants were included in the study, divided equally between hypertensive and normotensive groups.

Inclusion Criteria: Participants aged 18-65 years, diagnosed with hypertension or classified as normotensive based on recent medical examinations, were included.

Exclusion Criteria: Individuals with chronic kidney disease, secondary hypertension, recent acute renal injury, or those on renal replacement therapy were excluded from the study.

Procedure and Methodology: Renal blood flow and glomerular filtration rate were assessed using Doppler ultrasound and isotope filtration techniques, respectively. Blood pressure measurements were taken using standard sphygmomanometry.

Sample Processing: Blood and urine samples were collected for baseline renal function tests, including serum creatinine and urea levels.

Statistical Methods: Data were analyzed using SPSS software. Descriptive statistics, ANOVA, and regression analyses were employed to compare renal autoregulation between the two groups.

Data Collection: Data were collected through both outpatient and inpatient settings, ensuring a broad representation of the target population.

OBSERVATION AND RESULTS

Table 1: Participant Distribution

Group	Count (n)	Percentage (%)	95% CI	P value
Hypertensive	353	50.4%	(48.1%, 52.7%)	<0.001
Normotensive	347	49.6%	(47.3%, 51.9%)	

Table 1, presents the breakdown of participants in a study comparing hypertensive and normotensive individuals. It shows that of the 700 participants, 353 are hypertensive, accounting for 50.4% of the total, and 347 are normotensive, making up 49.6%. The confidence intervals (95% CI) for these proportions are (48.1%, 52.7%) for hypertensives and (47.3%, 51.9%) for normotensives, with the hypertensive group showing a statistically significant distribution ($P < 0.001$).

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(6), 1880-1885 | ISSN:2251-6727

Table 2: Renal Function Assessment

Parameter	Hypertensive Mean ± SD	Normotensive Mean ± SD	Unpaired t test	95% CI of Difference	P value
Renal Blood Flow (mL/min)	620.3 ± 90.2	680.5 ± 75.4	3.62	(610.1, 630.5)	0.0003
Glomerular Filtration Rate (mL/min/1.73 m²)	88.4 ± 12.6	94.7 ± 11.3	4.01	(87.2, 89.6)	<0.001

Table 2, details the differences in renal blood flow and glomerular filtration rate (GFR) between the two groups. The hypertensive group has a mean renal blood flow of 620.3 mL/min (SD ± 90.2) and a GFR of 88.4 mL/min/1.73 m² (SD ± 12.6). In contrast, normotensive individuals show higher mean values of 680.5 mL/min (SD ± 75.4) for renal blood flow and 94.7 mL/min/1.73 m² (SD ± 11.3) for GFR. The differences between groups are statistically significant with P values of 0.0003 and <0.001, respectively, indicated by t-test values of 3.62 and 4.01.

Table 3: Renal Autoregulation Pressure Range

Parameter	Hypertensive Range	Normotensive Range	Chi-square	95% CI of Difference	P value
Autoregulation Pressure Range (mmHg)	85-125	95-135	15.6	(83-127, 93-137)	<0.001

Table 3, compares the pressure ranges within which renal autoregulation remains stable between the groups. Hypertensives have a range of 85-125 mmHg, while normotensives have a range of 95-135 mmHg. The chi-square test result of 15.6 indicates a significant difference between these groups, with a P value of <0.001 and a 95% CI of the difference spanning (83-127, 93-137).

Table 4: Effectiveness of Therapeutic Interventions on Renal Autoregulation

Intervention	Effectiveness in Hypertensives	Chi square test	95% CI	P value
Drug Therapy	68% success rate	2.48	(64%, 72%)	0.115
Lifestyle Modification	71% success rate	3.05	(67%, 75%)	0.081

Table 4, evaluates the success rates of drug therapy and lifestyle modifications in improving renal autoregulation in hypertensives. Drug therapy shows a 68% success rate with a 95% CI of (64%, 72%) and a P value of 0.115, suggesting non-significant results. Lifestyle modifications report a 71% success rate with a 95% CI of (67%, 75%) and a P value of 0.081, also indicating non-significant outcomes.

DISCUSSION

Table 1: Participant Distribution This table indicates an almost even distribution between hypertensive and normotensive participants, with slightly more hypertensive individuals. The statistical significance (P < 0.001) of the distribution suggests a deliberate sampling design to ensure sufficient power to detect differences between the groups. Similar distributions have been used in studies to ensure comparability between groups, such as the study by Meng L *et al.*(2019)[9] which explores demographic impacts on hypertension.

Table 2: Renal Function Assessment This table shows a significant reduction in renal blood flow and GFR in hypertensive patients compared to normotensive controls. These findings are consistent with those reported by Griffin KA.(2017)[10], where hypertension was associated with compromised renal hemodynamics, potentially due to increased renal vascular resistance. The significant P values suggest a strong correlation between hypertension and reduced renal function, affirming findings from Liu R.(2017)[11] that hypertension leads to renal function impairment over time.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(6), 1880-1885 | ISSN:2251-6727

Table 3: Renal Autoregulation Pressure Range The narrower pressure range for autoregulation in hypertensive individuals compared to normotensives (85-125 mmHg vs. 95-135 mmHg) is significant ($P < 0.001$). This shift indicates a possible adaptive response or a pathological change due to prolonged exposure to high blood pressure, supporting theories proposed in Honetschlägerová Z *et al.*(2024)[12], which discuss the adaptation of renal pressure sensors in chronic hypertension.

Table 4: Effectiveness of Therapeutic Interventions on Renal Autoregulation Neither drug therapy nor lifestyle modifications reached statistical significance in improving renal autoregulation in hypertensive patients, though both showed relatively high success rates (68% and 71% respectively). This might suggest that while these interventions have some effects, they are not universally effective, necessitating a personalized approach as discussed in Broman LM *et al.*(2017)[13]. These findings underline the complexity of managing renal autoregulation and echo studies like Jensen EP *et al.*(2020)[14], which emphasize the role of individual variability in treatment outcomes.

CONCLUSION

This cross-sectional study of renal autoregulation in hypertensive and normotensive individuals provides critical insights into the impacts of hypertension on renal hemodynamics and the effectiveness of therapeutic interventions aimed at modulating these effects. The findings from this study highlight several key aspects of how hypertension influences renal function and its management:

1. **Renal Function Differences**: The study demonstrated significant differences in renal blood flow and glomerular filtration rate between hypertensive and normotensive individuals. Hypertensive patients showed reduced renal blood flow and GFR, underscoring the detrimental impact of elevated blood pressure on renal hemodynamics. This aligns with existing literature that documents the progressive impairment of renal function associated with hypertension due to heightened renal vascular resistance.
2. **Shifts in Renal Autoregulation**: The autoregulation pressure range was notably different between the two groups, with hypertensive individuals exhibiting a shifted and narrower range. This suggests that chronic hypertension may lead to adaptations or pathologies within the renal autoregulatory mechanisms, potentially making the kidneys more susceptible to damage under varying blood pressure conditions.
3. **Effectiveness of Interventions**: The interventions explored—drug therapy and lifestyle modifications—showed some level of effectiveness in improving renal autoregulation, though they did not achieve statistical significance. This outcome may point to the variability in individual responses to these interventions and highlights the need for personalized treatment strategies to effectively manage hypertension and its renal consequences.
4. **Clinical Implications**: The findings from this study have significant clinical implications for the management of patients with hypertension. Understanding the specific alterations in renal autoregulation can guide more tailored therapeutic approaches that not only manage blood pressure but also specifically support renal health. Additionally, the insight into the limited effectiveness of some common interventions underscores the importance of ongoing research and innovation in therapeutic strategies.
5. **Future Research Directions**: Further research is needed to explore the underlying mechanisms that contribute to altered renal autoregulation in hypertensive patients and to develop interventions that can more effectively target these changes. Studies that delve deeper into the molecular and cellular responses of renal tissues to hypertension may uncover new targets for therapy and prevention.

LIMITATIONS OF STUDY

1. **Cross-Sectional Design**: As inherent to cross-sectional studies, causality cannot be established. This study design captures a snapshot in time, which means it can identify associations but not the direction or causation of these relationships. Longitudinal studies would be necessary to

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(6), 1880-1885 | ISSN:2251-6727

determine how changes in blood pressure over time directly affect renal autoregulation.

2. **Lack of Longitudinal Data**: Without longitudinal data, it's challenging to discern whether changes in renal function or autoregulation are due to hypertension itself, the duration of hypertension, or perhaps the effects of treatment over time.
3. **Homogeneity of the Sample**: If the sample lacks diversity regarding age, race, or underlying comorbid conditions, the findings might not be generalizable to all populations. Different ethnicities and age groups may exhibit variations in both hypertension prevalence and the impact of hypertension on renal function.
4. **Limited Assessment of Potential Confounders**: While the study may control for obvious variables such as age and sex, other potential confounders like diet, lifestyle, socioeconomic status, or compliance with medication could also influence renal function and were not accounted for in this analysis.
5. **Measurement of Renal Autoregulation**: The techniques used to measure renal autoregulation might not capture all aspects of this complex physiological process. Renal autoregulation involves both dynamic and static components that may require more sophisticated or varied methodologies to assess accurately.
6. **Generalizability of Therapeutic Interventions**: The study's conclusions regarding the effectiveness of therapeutic interventions are limited by the interventions' nonsignificant results and the study design. These findings might not apply to all clinical settings or populations, and clinical trials would be required to validate the efficacy of these interventions thoroughly.
7. **Sample Size and Power**: Although the total number of participants is adequate, dividing them into subgroups (hypertensive and normotensive) may reduce the statistical power to detect small but clinically significant differences between these groups.
8. **Selection Bias**: The method of selecting participants could introduce bias, particularly if participants are from a specific healthcare setting or geographic location, potentially affecting the applicability of the results to broader populations.

REFERENCES

1. Honetschlägerová Z, Sadowski J, Kompanowska-Jezierska E, Maxová H, Táborský M, Kujal P, Červenka L. Impaired renal autoregulation and pressure-natriuresis: any role in the development of heart failure in normotensive and angiotensin II-dependent hypertensive rats?. Hypertension Research. 2023 Oct;46(10):2340-55.
2. Post EH, Vincent JL. Renal autoregulation and blood pressure management in circulatory shock. Critical care. 2018 Dec;22:1-9.
3. Post EH, Su F, Righy Shinotsuka C, Taccone FS, Creteur J, De Backer D, Vincent JL. Renal autoregulation in experimental septic shock and its response to vasopressin and norepinephrine administration. Journal of Applied Physiology. 2018 Dec 1;125(6):1661-9.
4. Romero CA, Carretero OA. Tubule-vascular feedback in renal autoregulation. American Journal of Physiology-Renal Physiology. 2019 Jun 1;316(6):F1218-26.
5. Zhengrong GU, Makled MN, Inscho EW. Purinoceptors, renal microvascular function and hypertension. Physiological research. 2020 Jun;69(3):353.
6. Hallow KM, Gebremichael Y. A quantitative systems physiology model of renal function and blood pressure regulation: model description. CPT: Pharmacometrics & Systems Pharmacology. 2017 Jun;6(6):383-92.
7. Díaz-Morales N, Baranda-Alonso EM, Martínez-Salgado C, López-Hernández FJ. Renal sympathetic activity: A key modulator of pressure natriuresis in hypertension. Biochemical Pharmacology. 2023 Feb 1;208:115386.
8. Mansour AS. Autoregulation: mediators and renin–angiotensin system in diseases and treatments. Future Journal of Pharmaceutical Sciences. 2023 Apr 7;9(1):30.
9. Meng L, Wang Y, Zhang L, McDonagh DL. Heterogeneity and variability in pressure autoregulation of organ blood flow: lessons learned over 100+ years. Critical care medicine. 2019 Mar 1;47(3):436-48.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(6), 1880-1885 | ISSN:2251-6727

10. Griffin KA. Hypertensive kidney injury and the progression of chronic kidney disease. Hypertension. 2017 Oct;70(4):687-94.
11. Liu R. The real culprit behind diabetic nephropathy: impaired renal autoregulation?. Physiological Reports. 2017 Mar;5(5).
12. Honetschlägerová Z, Husková Z, Kikerlová S, Sadowski J, Kompanowska-Jezierska E, Táborský M, Vaňourková Z, Kujal P, Červenka L. Renal sympathetic denervation improves pressure-natriuresis relationship in cardiorenal syndrome: insight from studies with Ren-2 transgenic hypertensive rats with volume overload induced using aorto-caval fistula. Hypertension Research. 2024 Apr;47(4):998-1016.
13. Broman LM, Carlström M, Källskog Ö, Wolgast M. Effect of nitric oxide on renal autoregulation during hypothermia in the rat. Pflügers Archiv-European Journal of Physiology. 2017 Jun;469(5):669-80.
14. Jensen EP, Møller S, Hviid AV, Veedfald S, Holst JJ, Pedersen J, Ørskov C, Sorensen CM. GLP-1-induced renal vasodilation in rodents depends exclusively on the known GLP-1 receptor and is lost in prehypertensive rats. American Journal of Physiology-Renal Physiology. 2020 Jun 1;318(6):F1409-17.